Pasar al contenido principal

NEURODEGENERACION RETINANA: BIOMARCADORES GENETICOS Y NUEVAS APROXIMACIONES TERAPEUTICAS

PID2020-114585RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE VALLADOLID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Programmed cell death and autophagy in an in vitro model of spontaneous neuroretinal degeneration

  • Puertas-Neyra, Kevin
  • Galindo-Cabello, Nadia
  • Hernández-Rodríguez, Leticia A.
  • González-Pérez, Fernando
  • Rodríguez-Cabello, José Carlos
  • González-Sarmiento, Rogelio
  • Pastor, José Carlos
  • Usategui-Martín, Ricardo
  • Fernández-Bueno, Iván
Retinal neurodegenerative diseases are the leading causes of visual impairment and irreversible blindness worldwide. Although the retinal response to injury remains closely similar between different retinal neurodegenerative diseases, available therapeutic alternatives are only palliative, too expensive, or very specific, such as gene therapy. In that sense, the development of broad-spectrum neuroprotective therapies seems to be an excellent option. In this regard, it is essential to identify molecular targets involved in retinal degeneration, such as cell death mechanisms. Apoptosis has been considered as the primary cell death mechanism during retinal degeneration; however, recent studies have demonstrated that the only use of anti-apoptotic drugs is not enough to confer good neuroprotection in terms of cell viability and preservation. For that reason, the interrelationship that exists between apoptosis and other cell death mechanisms needs to be characterized deeply to design future therapeutic options that simultaneously block the main cell death pathways. In that sense, the study aimed to characterize the programmed cell death (in terms of apoptosis and necroptosis) and autophagy response and modulation in retinal neurodegenerative diseases, using an in vitro model of spontaneous retinal neurodegeneration. For that purpose, we measured the mRNA relative expression through qPCR of a selected pool of genes involved in apoptosis (BAX, BCL2, CASP3, CASP8, and CASP9), necroptosis (MLKL, RIPK1, and RIPK3), and autophagy (ATG7, BCLIN1, LC3B, mTOR, and SQSTM1); besides, the immunoexpression of their encoding proteins (Casp3, MLKL, RIPK1, LC3B, and p62) were analyzed using immunohistochemistry. Our results showed an increase of pro-apoptotic and pro-necroptotic related genes and proteins during in vitro retinal neurodegeneration. Besides, we describe for the first time the modulation between programmed cell death mechanisms and autophagy in an in vitro retinal neurodegeneration model. This study reinforces the idea that cell death mechanisms are closely interconnected and provides new information about molecular signaling and autophagy along the retinal degeneration process., The authors are grateful for the funding from the Spanish Government (PID2019-110709RB-100, RED2018-102417-T, FPU16/04015, PID2020-114585RA-I00, and PID2020-118860RB-I00), Junta de Castilla y León (VA317P18, Infrared2018-UVA06), Interreg V España Portugal POCTEP (0624_2IQBIONEURO_6_E) and Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León. KP-N was funded by Fundación Carolina, the call for predoctoral contracts UVa2020 (co-funded by Santander Bank) and predoctoral contracts of the Junta de Castilla y Leon 2021.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Retinal neuroprotective effect of mesenchymal stem cells secretome through modulation of oxidative stress, autophagy, and programmed cell death

  • Usategui-Martín, Ricardo
  • Puertas-Neyra, Kevin
  • Galindo-Cabello, Nadia
  • Hernández-Rodríguez, Leticia A.
  • González-Pérez, Fernando
  • Rodríguez-Cabello, José Carlos
  • González-Sarmiento, Rogelio
  • Pastor, José Carlos
  • Fernández-Bueno, Iván
[Purpose]: Degenerative mechanisms of retinal neurodegenerative diseases (RND) share common cellular and molecular signalization pathways. Curative treatment does not exist and cell-based therapy, through the paracrine properties of mesenchymal stem cells (MSC), is a potential unspecific treatment for RND. This study aimed to evaluate the neuroprotective capability of human bone marrow (bm) MSC secretome and its potential to modulate retinal responses to neurodegeneration. [Methods]: An in vitro model of spontaneous retinal neurodegeneration was used to compare three days of monocultured neuroretina (NR), NR cocultured with bmMSC, and NR cultured with bmMSC secretome. We evaluated retinal morphology markers (Lectin peanut agglutinin, rhodopsin, protein kinase C α isoform, neuronal-specific nuclear protein, glial fibrillary acidic protein, TdT-mediated dUTP nick-end labeling, and vimentin) and proteins involved in apoptosis (apoptosis-inductor factor, caspase-3), necroptosis (MLKL), and autophagy (p62). Besides, we analyzed the relative mRNA expression through qPCR of genes involved in apoptosis (BAX, BCL2, CASP3, CASP8, CASP9), necroptosis (MLKL, RIPK1, RIPK3), autophagy (ATG7, BCLIN1, LC3B, mTOR, SQSTM1), oxidative stress (COX2, CYBA, CYBB, GPX6, SOD1, TXN2, TXNRD1) and inflammation (IL1, IL6, IL10, TGFb1, TNFa). [Results]: The bmMSC secretome preserves retinal morphology, limits pro-apoptotic– and pro-necroptotic–related gene and protein expression, modulates autophagy-related genes and proteins, and stimulates the activation of antioxidant-associated genes. [Conclusions]: The neuroprotective ability of the bmMSC secretome is associated with activation of antioxidant machinery, modulation of autophagy, and inhibition of apoptosis and necroptosis during retinal degeneration. The neuroprotective effect of bmMSC secretomes in the presence/absence of MSC looks similar. Our current results reinforce the hypothesis that the human bmMSC secretome slows retinal neurodegeneration and may be a therapeutic option for treating RND., Supported by the Spanish Government (PID2019-110709RB100, RED2018-102417-T, FPU16/04015, PID2020-114585RAI00 and PID2020-118860RB-I00), Junta de Castilla y León (VA317P18, Infrared2018-UVA06, and GRS1928/A/19), Interred V España Portugal POCTEP (0624_2IQBIONEURO_6_E), and Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León. Ricardo Usategui-Martín was funded by the call for postdoctoral contracts UVa2018. Kevin Puertas-Neyra was funded by Fundación Carolina, the call for predoctoral contracts UVa2020 (co-funded by Santander Bank) and predoctoral contracts of the Junta de Castilla y Leon 2021.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Missense Variant in TP53 Could Be a Genetic Biomarker Associated with Bone Tissue Alterations

  • Usategui-Martín, Ricardo
  • Galindo-Cabello, Nadia
  • Pastor-Idoate, Salvador
  • Fernández-Gómez, José María
  • Del Real, Álvaro
  • Ferreño, Diego
  • Lapresa, Rebeca
  • Martín-Rodriguez, Francisco
  • Riancho, José A.
  • Almeida, Angeles
  • Pérez-Castrillón, José Luis
Metabolic bone diseases cover a broad spectrum of disorders that share alterations in bone metabolism that lead to a defective skeleton, which is associated with increasing morbidity, disability, and mortality. There is a close connection between the etiology of metabolic bone diseases and genetic factors, with TP53 being one of the genes associated therewith. The single nucleotide polymorphism (SNP) Arg72Pro of TP53 is a genetic factor associated with several pathologies, including cancer, stroke, and osteoporosis. Here, we aim to analyze the influence of the TP53 Arg72Pro SNP on bone mass in humanized Tp53 Arg72Pro knock-in mice. This work reports on the influence of the TP53 Arg72Pro polymorphism in bone microarchitecture, OPG expression, and apoptosis bone status. The results show that the proline variant of the TP53 Arg72Pro polymorphism (Pro72-p53) is associated with deteriorated bone tissue, lower OPG/RANK ratio, and lower apoptosis in bone tissue. In conclusion, the TP53 Arg72Pro polymorphism modulates bone microarchitecture and may be a genetic biomarker that can be used to identify individuals with an increased risk of suffering metabolic bone alterations., This research was funded by Ministerio de Ciencia e Innovación (Spain Government; PID2020-114585RA-I00 to RUM and SPI) and Instituto de Salud Carlos III (Spain; PI21/00727 to AA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The TP53 Arg72Pro polymorphism predicts visual and neurodegenerative outcomes in retinal detachment

  • Galindo-Cabello, Nadia
  • Sobas-Abad, Eva M.
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
  • López, Antonio
  • Pastor-Pareja, José Carlos
  • Pastor-Idoate, Salvador
  • Usategui-Martín, Ricardo
Retinal detachment (RD) separates the retina from the retinal epithelium, causing photoreceptor apoptosis and irreversible vision loss. Even with successful surgical reattachment, complete visual recovery is not guaranteed. The TP53 Arg72Pro polymorphism, implicated in apoptosis, has emerged as a potential predictor of RD outcomes. We investigated the impact of the Arg72Pro polymorphism on retinal neurodegeneration and functional recovery in patients. The underlying mechanisms were analyzed in a humanized TP53 Arg72Pro RD mouse model. In a cohort of 180 patients, carriers of the Pro allele exhibited decreased apoptotic gene expression and improved visual recovery. Complementary findings in mice revealed that the Pro variant preserved photoreceptor integrity and reduced apoptosis rates following RD. Our findings highlight the potential of this TP53 polymorphism as a biomarker for RD outcomes and a tool for tailoring therapies. This study underscores the importance of integrating genetic profiling into personalized medicine approaches to improve recovery of RD patients’ visual outcomes., We express our gratitude to the patients for their participation, to the University of Valladolid’s Animal Welfare and Research Service for their care and technical support, and to the operating room nurses from both the University Clinic Hospital of Valladolid and the IOBA Eye Institute at the University of Valladolid for assisting in blood sample collection. This study was supported by MICIU/AEI (PID2020-114585RA-I00, PID2023-147958OB-I00, and PDC2023-145857-100 to S.P.I. and R.U.M.) (as appropriate, by the European Union Next Generation EU/PRTR) and the Instituto de Salud Carlos III (RD21/0002/0017 and RD24/0007/0008 to S.P.I., PI21/00727 and RD21/0006/0005 to A.A.). Programa estratégico IOBA from Junta de Castilla y León (Spain) (CLU-2023-1-04 to S.P.I and R.U.M)., Peer reviewed